Breaking News

Argentina Didn't Reach an Agreement With Holdouts: Mediator

Bayer Stops Regorafenib Trial Early on Positive Phase III Data

Bayer AG (BAYN) announced positive results from its phase III trial evaluating regorafenib compound for the treatment of patients with metastatic colorectal cancer whose disease has progressed after approved standard therapies. The trial met its primary endpoint of statistically significantly improving overall survival and patients in the placebo arm will be offered treatment with regorafenib, the company said in an e-mailed statement today.

To contact the editor responsible for this story: Mariajose Vera at

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.